Letters To The Editor
- Zhong et al. (1) characterize PRN694, a dual inhibitor of ITK and resting lymphocyte kinase (RLK). They demonstrate activity against T-cell receptor (TCR) signaling in T-PLL and suggest a therapeutic application. However, an actual TCR dependence of T-PLL is not established (2), and cytotoxic consequences of inhibited kinase activation in T-PLL cells by PRN694 (1) or various other ITK inhibitors (3) are not reported.